Platelet treatment guidance method based on drug gene polymorphism and thromboelastography

Abstract

The invention relates to the technical field of platelets, in particular to a platelet treatment guidance method based on drug gene polymorphism and thromboelastography. The method comprises the following steps: S1, drug gene detection; S2, whole blood genome DNA sequencing; S3, metabolic classification; S4, TEG detection; and S5, result analyzing. In the invention, the risk of new stroke within 90d can be effectively reduced by guiding the anti-platelet treatment of the mild ischemic stroke according to the drug gene polymorphism in combination with TEG, and the bleeding risk is not increased. The gene detection is combined with the TEG, so that patients insensitive to antiplatelet drug therapy can be found in time, a new basis for selection of anti-platelet treatment drugs is provided, patients with ischemic stroke can select the anti-platelet drugs more accurately and reasonably, an individualized anti-platelet treatment scheme is formulated, the risk of stroke recurrence is effectively reduced, and the method has important guiding significance for secondary prevention of ischemic stroke and is worthy of clinical popularization and application.

Description

technical field [0001] The invention relates to the technical field of platelets, in particular to a platelet treatment guidance method based on drug gene polymorphism and thromboelastogram. Background technique [0002] Patients with minor ischemic stroke are at high short-term risk of subsequent stroke, which is likely to result in disability, especially in the first 90 days after stroke. The CHANCE study found that administration of aspirin combined with clopidogrel within 24 hours after minor ischemic stroke or transient ischemic attack (TIA) for 21 days could reduce the risk of stroke recurrence by 32% compared with aspirin alone, and did not increase bleeding complications. The secondary analysis of the POINT study also confirmed that the use of dual-antibody therapy in the first 21 days after the onset of disease has the greatest benefit in reducing ischemic events, and the benefit of continuing to use dual-antibody therapy after 21 days will be offset by the increase...

AI Technical Summary

Problems solved by technology

The mechanism of AR and CR is relatively complicated, and it is not very clear at present. Previous studies have shown that related gene polymorphisms involved in the metabolism and action of antiplatelet drugs may be an important factor

At present, there is no individualized and standardized antiplatelet therapy system based on the condition of Chinese people in China